Jazz Pharmaceuticals (JAZZ) PT Raised to $280 at Baird
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $240.07 -2.73%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 26 | Down: 25 | New: 65
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 26 | Down: 25 | New: 65
Join SI Premium – FREE
Baird analyst Brian Skorney raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $280.00 (from $252.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Canaan Inc. (CAN) PT Lowered to $2 at BTIG
- Roivant Sciences (ROIV) PT Raised to $55 at Piper Sandler
- JPMorgan Upgrades Telekom Malaysia Bhd (T:MK) (MYTEF) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
